Toronto Stock Exchange · Healthcare
Invest in Cannara Biotech stock from India
Indian and foreign residents can buy Cannara Biotech (LOVE) shares directly through Paasa.
By Paasa · Updated
Cannara Biotech at a glance
- Price
- CA$2.20+CA$0.04 (1.85%)
- Market cap
- CA$217.32M
- Day range
- CA$2.12 – CA$2.20
- P/E
- 19.37
- Dividend yield
- None
- Volume
- 15.39K
- 1 month
- +10.55%
- 6 months
- +22.22%
- YTD
- +26.44%
- 1 year
- +21.55%
- 5 years
- +46.67%
Cannara Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CA$107.3M | CA$81.7M | CA$57.3M | CA$35.8M | CA$17.0M |
| Gross profit | CA$47.2M | CA$29.8M | CA$27.2M | CA$16.7M | CA$11.9M |
| Operating income | CA$22.2M | CA$10.1M | CA$11.9M | CA$4.4M | CA$1.8M |
| Net income | CA$13.1M | CA$6.4M | CA$6.9M | CA$2.3M | −CA$1.5M |
| Earnings per share | CA$0.14 | CA$0.07 | CA$0.08 | CA$0.03 | −CA$0.04 |
| EBITDA | CA$28.2M | CA$15.2M | CA$15.8M | CA$7.8M | CA$4.6M |
| Total assets | CA$168.6M | CA$154.7M | CA$141.5M | CA$125.6M | CA$92.0M |
| Total debt | CA$41.6M | CA$48.3M | CA$45.8M | CA$48.4M | CA$20.9M |
| Cash and short-term investments | CA$14.4M | CA$6.6M | CA$4.3M | CA$12.1M | CA$8.2M |
| Shareholders' equity | CA$102.2M | CA$88.0M | CA$79.7M | CA$66.7M | CA$64.1M |
| Operating cash flow | CA$20.0M | CA$10.7M | CA$5.9M | −CA$6.1M | −CA$2.1M |
| Free cash flow | CA$13.7M | CA$3.2M | −CA$4.0M | −CA$21.5M | −CA$33.2M |
| Capital expenditure | −CA$6.4M | −CA$7.5M | −CA$9.9M | −CA$15.5M | −CA$31.1M |
Fiscal years as reported, the latest ending 31 Aug 2025. Figures in CAD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Auxly Cannabis | XLY.TO | CA$3.61 | CA$365.79M |
| Cardiol Therapeutics | CRDL.TO | CA$2.41 | CA$277.81M |
| Satellos Bioscience | MSCL.TO | CA$12.20 | CA$254.14M |
| Quipt Home Medical | QIPT.TO | CA$4.98 | CA$221.44M |
| BioSyent | RX.V | CA$16.78 | CA$191.93M |
| Jushi | JUSH.CN | $0.90 | $179.73M |
| Grown Rogue International | GRIN.CN | $0.63 | $157.46M |
| HLS Therapeutics | HLS.TO | CA$3.99 | CA$124.79M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Cannara Biotech from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CAD when you buy.
Step 3
Search LOVE and buy
Find Cannara Biotech by name or by its ticker, LOVE, and place your order.
Why invest in Cannara Biotech from India
What Cannara Biotech does
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Cannara Biotech operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Cannara Biotech stock from India?
Yes. Indian residents and NRIs can buy Cannara Biotech (LOVE) shares directly through Paasa. Cannara Biotech is listed on the Toronto Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Cannara Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CAD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.